A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA).
Zsuzsanna H McMahanChristopher P DentonDaniel E FurstMaureen D MayesMarco Matucci-CerinicVanessa SmithDick de VriesPaul FordYasmina BauerMatthew J RandallMitra EbrahimpoorLaszlo KupcsikPieter-Jan StiersLiesbeth DeberdtNiyati PrasadSharlene LimPhilippe PujuguetSohail AhmedPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
Ziritaxestat resulted in significantly greater reductions in mRSS at Week 24 than placebo; no new safety signals emerged. Biomarker analysis suggests ziritaxestat may reduce fibrosis. Modulation of the autotaxin/LPA pathway could improve skin involvement in patients with dcSSc. A plain language summary is available in the Supplement.